Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model

Blanco, Jorge C. G.; McGinnes-Cullen, Lori; Otoa, Raymonde O.; Patel, Manan S.; Fernando, Lurds R.; Boukhvalova, Marina S.; Morrison, Trudy G.

doi:10.1038/s41467-018-04216-6

Cited by 39 publications

(112 citation statements)

References 29 publications

(53 reference statements)

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…The purpose of the reported study was to evaluate the safety and efficacy of maternally transferred antibodies in preventing RSV in infants. The vaccinated healthy third-trimester pregnant women showed significant protection to newborn children from RSV challenge and reduced pulmonary inflammation, and the vaccine was safe and effective for maternal and adult vaccination [44]. Furthermore, this company is working in recombinant trivalent nanoparticle influenza vaccine with matrix M-1.…”

Section: Np-investing Companies and Clinical Trialsmentioning

confidence: 99%

“…The third clinical study is in phase three trials and will finish in July 2019. The vaccine is safe and effective for infants and pregnant women [44]. The study "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine with Matrix M-1 Adjuvant (NanoFlu)" was used to test protection in people older than age 60, but no results have been publicly released.…”

Section: Np-investing Companies and Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle-based vaccines

Díaz-Arévalo

Zeng

2020

Nanopharmaceuticals

View full text Add to dashboard Cite

Section: Np-investing Companies and Clinical Trialsmentioning

confidence: 99%

Section: Np-investing Companies and Clinical Trialsmentioning

confidence: 99%

Nanoparticle-based vaccines

Díaz-Arévalo

Zeng

2020

Nanopharmaceuticals

View full text Add to dashboard Cite

“…RSV F nanoparticle protein or chimeric NDV-RSV VLP-induced immunity could be transferred from mothers to the infants [119]. Pregnant cotton rats were intramuscularly immunized with RSV pre-fusion F/G VLP or RSV F nanoparticle protein vaccines to evaluate the protective role of maternally transferred immunity in infants through the placental barrier [119,120]. The offspring pups born to vaccinated cotton rats were protected against RSV infection and pulmonary inflammation [120].…”

Section: Vaccine Efficacy Of Rsv Vlp Vaccinesmentioning

confidence: 99%

“…Pregnant cotton rats were intramuscularly immunized with RSV pre-fusion F/G VLP or RSV F nanoparticle protein vaccines to evaluate the protective role of maternally transferred immunity in infants through the placental barrier [119,120]. The offspring pups born to vaccinated cotton rats were protected against RSV infection and pulmonary inflammation [120]. RSV F nanoparticle protein vaccine induced polyclonal palivizumab-competitive high neutralizing activities against RSV A and B viruses after active and passive immunization of cotton rats [119].…”

Section: Vaccine Efficacy Of Rsv Vlp Vaccinesmentioning

confidence: 99%

Progress in the development of virus-like particle vaccines against respiratory viruses

Quan

Basak

Chu

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Influenza virus, human respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses. Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV, and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered includes VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties, and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article. Expert opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted. ARTICLE HISTORY

show abstract

“…We have reported that VLPs assembled with the DS-Cav1 mutant F protein stimulate, in mice and in cotton rats, neutralizing antibody titers much higher than those induced by VLPs assembled with the post-fusion F protein or wild-type F protein [16,22]. Furthermore, the immunization of cotton rat dams with DS-Cav1 F VLPs protected their offspring from RSV challenge [14].Since the description of DS-Cav1 F protein, a number of other laboratories and companies have identified different sets of mutations that reportedly stabilize the pre-fusion F protein [23][24][25][26][27][28][29]. A very important question for vaccine development is whether the different mutation-stabilized pre-fusion F proteins are indeed the same in terms of structure, antibodies induced, and protection from RSV challenge afforded by their use as immunogens.…”

mentioning

confidence: 99%

Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring

et al. 2020

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) infection poses a significant risk for infants. Since the direct vaccination of infants is problematic, maternal vaccination may provide a safer, more effective approach to their protection. In the cotton rat (CR) model, we have compared the immunization of pregnant CR dams with virus-like particles assembled with the prototype mutation stabilized pre-fusion F protein, DS-Cav1, as well two alternative mutation stabilized pre-fusion proteins (UC-2 F, UC-3 F) and showed that the alternative pre-fusion F VLPs protected the offspring of immunized dams significantly better than DS-Cav1 F VLPs (Blanco, et al. J. Virol. 93: e00914). Here, we have addressed the reasons for this increased protection by characterizing the specificities of antibodies in the sera of both immunized dams and their offspring. The approach was to measure the levels of total anti-pre-F IgG serum antibodies that would block the binding of representative pre-fusion specific monoclonal antibodies to soluble pre-fusion F protein targets. Strikingly, we found that the sera in most offspring of DS-Cav1 F VLP-immunized dams had no mAb D25-blocking antibodies, although their dams had robust levels. In contrast, all offspring of UC-3 F VLP-immunized dams had robust levels of these D25-blocking antibodies. Both sets of pup sera had significant levels of mAb AM14-blocking antibodies, indicating that all pups received maternal antibodies. A lack of mAb D25-blocking antibodies in the offspring of DS-Cav1 F VLP-immunized dams may account for the lower protection of their pups from challenge compared to the offspring of UC-3 F VLP-immunized dams.Vaccines 2020, 8, 133 2 of 15 to infectious, attenuated, or vector viruses, since they do not contain a genome and do not produce a spreading infection. Our VLPs are based on the core proteins of Newcastle disease virus (NDV), NP and M proteins, and they are assembled with the RSV F and G protein ectodomains fused to the transmembane and cytoplasmic domains of the NDV F and HN proteins, respectively.There has been a resurgence of interest and activity in RSV vaccine development due to the ground-breaking studies of McLellan, et al. who succeeded in solving the crystal structure of the RSV pre-fusion F protein and identifying a set of mutations in the F protein, termed DS-Cav1, which stabilized the pre-fusion form of the F protein [20,21]. We have reported that VLPs assembled with the DS-Cav1 mutant F protein stimulate, in mice and in cotton rats, neutralizing antibody titers much higher than those induced by VLPs assembled with the post-fusion F protein or wild-type F protein [16,22]. Furthermore, the immunization of cotton rat dams with DS-Cav1 F VLPs protected their offspring from RSV challenge [14].Since the description of DS-Cav1 F protein, a number of other laboratories and companies have identified different sets of mutations that reportedly stabilize the pre-fusion F protein [23][24][25][26][27][28][29]. A very important question for vaccine development is whether the different m...

show abstract

Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model

Cited by 39 publications

References 29 publications

Nanoparticle-based vaccines

Nanoparticle-based vaccines

Progress in the development of virus-like particle vaccines against respiratory viruses

Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring

Contact Info

Product

Resources

About